Medicure Inc. · TSXV:MPH
Medicure — Investor Presentation (April 2023)
15 slides from Medicure's investor presentation, April 2023
Slide 1: Investor Presentation
Medicure Inc. Investor Presentation MPH:TSXV April 2023
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation is for informational purposes only and should not be considered as an offer to buy or sell securities. No stock exchange has either approved or disapproved of the information that is contained in this presentation. This presentation may contain forward-loo
Slide 3: Why Invest in Medicure
Why Invest in Medicure Medicure is a profitable R&D specialty pharmaceutical company focused on the US market with an E-commerce pharmacy Profitable and Steady sales of Growing sales of growing profit AGGRASTAT ZYPITAMAG Marley Drug MC-1: priority review voucher No debt e-Commerce pharmacy upon comp
Slide 4: Progress and Profitability
Progress and Profitability 2022 EPS: $0.13 6% 42% $10.0 $25.0 $4.0 2.1M $5.0 $3.0 $20.0 $2.0 $0.0 $1.0 $15.0 -$5.0 $CAD (M) $0.0 -$1.0 -$10.0 $10.0 -$2.0 -$15.0 $5.0 -$3.0 -$20.0 -$4.0 $0.0 -$5.0 -$25.0 2019 2020 2021 2022 2019 2020 2021 2022 2019 2020 2021 2022 Net Revenue Adjusted EBITDA Net Incom
Slide 5: Medicure’s Leadership Team
Medicure’s Leadership Team Reuben Saba Haaris Uddin Albert D. Friesen Neil Owens Vice President, Chief Financial Officer Chief Executive Officer & President & Chairman of the Board Chief Operating Officer Medical and Business Affairs • Founded Medicure in 1997 • President & COO since 2019 • VP since
Slide 6: AGGRASTAT: Leading IV antiplatelet in its class
INDICATION $11.7M Acute Coronary Syndrome In 2022 PRODUCT HIGHLIGHTS • Leading IV antiplatelet in its class 1.3% • Medicure grew market share from 2% to 65% from the prior year • Used in more than 1,200 hospitals • Three formats of the product available $25M GPIIb/IIIa market* MPH:TSXV *Estimated
Slide 7: ZYPITAMAG: Improvements over older statins
INDICATION $ 3.6M High Cholesterol In 2022 PRODUCT HIGHLIGHTS • Improvements over older statins 12% • Low rates of side effects like muscle pain from the prior year • Doesn’t interact with other medications • Once daily low dose with strong LDL reduction $ 4B US Statin market* MPH:TSXV *Estimated
Slide 8: ZYPITAMAG Customer Quotes
ZYPITAMAG Customer Quotes Zypitamag is a great option. The results are back after 2 Zypitamag just works for I personally tried multiple It's nice to be able to skip months on Zypitamag. Wow! me. And, it's affordable. I statins and had intolerable the "pain" of step therapy don't even use my side ef
Slide 9: Medicure’s Pharmacy Subsidiary and E-Commerce Platform
Medicure’s Pharmacy Subsidiary and E-Commerce Platform WHAT IS MARLEY DRUG • A US pharmacy subsidiary licensed to ship FDA approved $7.8M medications to all 50 states In 2022 • Facilitates Medicure selling ZYPITAMAG directly to consumers HIGHLIGHTS 12% • More than 100,000 customers from the prior ye
Slide 10: Marley Drug Customer Quotes
Marley Drug Customer Quotes I really love Marley’s quick The Wholesale Price List As soon as my doctor Check out this pharmacy. responses and the fact that made my prescription submitted the prescription, My cardiologist referred I can purchase a 6-month easy to afford. My monthly I was contacted by
Slide 11: Why Did Medicure Acquire Marley Drug
Why Did Medicure Acquire Marley Drug • A more efficient distribution and marketing vehicle for ZYPITAMAG – a branded drug • A marketing vehicle for other branded drugs • Saves on high fees to wholesalers and pharmacy benefit managers Watch our explainer video here MPH:TSXV
Slide 12: Development of MC-1 for Rare Pediatric Disease
PHASE 3 CLINICAL STUDY Development of MC-1 for Rare Pediatric Disease Phase 3 study for treatment of rare pediatric disease called PNPO deficiency • Study involves 10-15 patients in US and Australia • Orphan drug status • If approved Medicure is eligible for a priority review voucher, which can be r
Slide 13: Medicure’s Growth Strategy
Medicure’s Growth Strategy Medicure plans to use its profit to fund R&D and acquisitions Medicure is profitable Funding R&D of MC-1 Exploring acquisition through AGGRASTAT, and beyond opportunities of other ZYPITAMAG and Marley pharmaceutical products and Drug to build the Marley Drug business MPH:T
Slide 14: Key Takeaways About Medicure
5 Key Takeaways About Medicure 1. Medicure’s focus is on pharmaceuticals and healthcare products for the US market 2. Proven success with AGGRASTAT, building sales of ZYPITAMAG 3. Focus on direct consumer sales for growth and profitability through Marley Drug pharmacy subsidiary 4. R&D focus on MC-1
Slide 15: Thank You for Your Interest
Thank You for Your Interest For Further Information Visit our Websites Investor Relations Medicure.com ir@medicure.com AGGRASTAT.com 1-888-435-2220 (Ext. 228) ZYPITAMAG.com Marley Drug.com Follow us on LinkedIn MPH:TSXV